Searchable abstracts of presentations at key conferences in endocrinology

ea0056s27.3 | Emerging treatments in osteoporosis | ECE2018

Sequential and combination therapy for osteoporosis.

Belaya Zhanna

Over past years various treatment options for osteoporosis have become available and withdrawn due to side effects or insufficient efficacy. This summary reviews sequential and combination therapy for osteoporosis with the currently approved first line treatments such as potent antiresorbtive (nitrogen-containing bisphosphonates (BP), denosumab (DM)) or anabolic agents (teriparatide, abaloparatide). We assume that all medications are taken with vitamin D and calcium supplement...

ea0081ep742 | Pituitary and Neuroendocrinology | ECE2022

Hypophysitis and reversible hypopituitarism developed after COVID-19 infection - a clinical case report.

Gorbova Natalia , Rozhinskaya Liudmila , Vladimirova Viktoria , Belaya Zhanna

Aim: To present a clinical case of reversible hypopituitarism due to hypophysitis developed after COVID-19 infection.Materials and methods: A patient with residual clinical manifestations of hypopituitarism underwent clinical evaluation at the time of symptoms of hypopituitarism and in follow-up. Morning serum cortisol (171-536 nmol/l) was measured by electrochemiluminescence immunoassay. Morning ACTH (7.2-63.3 pg/ml), prolactin (66-436 mU/l), TSH (0.25-...

ea0063gp113 | Calcium and Bone 2 | ECE2019

Vertebral fracture in outpatients with type 2 diabetes mellitus

Yalochkina Tatiana , Tarbaeva Natalia , Rozhinskaya Liudmila , Nikankina Larisa , Belaya Zhanna

According to numerous studies, type 2 diabetes mellitus (T2DM) is associated with an increased risk of low traumatic non-vertebral fracture. There are a limited number of studies which evaluate lateral vertebral X-Rays in order to diagnose vertebral fractures in patients with T2DM. The goal of our study was to investigate the difference in vertebral fracture rate registered on lateral X-Ray between subjects with T2DM and a control group being under observation in the same outp...

ea0063p81 | Calcium and Bone 1 | ECE2019

A rare case of hypoparathyroidism due to MELAS syndrome

Grebennikova Tatiana , Zenkova Tatjana , Tarbaeva Natalia , Sorkina Ekaterina , Belaya Zhanna

MELAS syndrome is a progressive neurodegenerative disorder characterized by a combination of mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes and endocrine disorders. The frequency of hypoparathyroidism in MELAS syndrome is less than 0.5%. A 22-year-old female was admitted to our center due to episodes of seizures. At admission her height was 147.5 cm, weight 30.5 kg, BMI 13.8 kg/m2. She reported whole life weight and growth retardation, hearin...

ea0063p1117 | Pituitary and Neuroendocrinology 3 | ECE2019

Epidemiology of acromegaly in Russian Federation: evaluation of National registry-based data

Lutsenko Alexander , Przhiyalkovskaya Elena , Pigarova Ekaterina , Belaya Zhanna , Rozhinskaya Liudmila

According to state statistics service, Russia’s population in 2018 is more than 146.8 mil people. The total prevalence of acromegaly may range between 2.8 and 13.7 cases per 100,000 people and the annual incidence rates vary between 0.2 and 1.1 cases per 100,000 people (Lavrentaki A, et al. 2016). The epidemiological data for acromegaly in Russian population is lacking. The Russian hypothalamic and pituitary tumors registry was founded in 2004 and for 2018 it con...

ea0049ep1034 | Pituitary - Clinical | ECE2017

Pregnancy outcome in women with prolactinomas exposed to dopamine agonists at early stages of gestation

Vorotnikova Svetlana , Skuridina Darya , Dzeranova Larisa , Pigarova Ekaterina , Belaya Zhanna

Introduction: Medical therapy with dopamine agonists is the best treatment for prolactinomas of any size or invasiveness and restores ovulatory cycles in 80–90% of patients. Cabergoline currently suggested nearly exclusively rather than other dopamine agonists due to its excellent tolerability and long half-life. That is why the question of safety using of this drug during pregnancy and embryo-fetal development is actual.Aim: The aim of the study is...

ea0035p24 | Adrenal cortex | ECE2014

Bone mineral density, markers of bone remodeling, and quality of life in patients with Cushing's syndrome after 12 months of remission

Dragunova Natalja , Belaya Zhanna , Rozhinskaya Liudmila , Melnichenko Galina

This study estimates the recovery of bone mineral density (BMD), markers of bone remodeling and quality of life in patients with endogenous Cushing’s syndrome (CS) after 12 months of remission.Materials and methods: Twenty-one patients with CS were prospectively evaluated at active stage of the disease and after being in a full remission (substitutional therapy with hydrocortisone or normal 24 h urinary free cortisol (24 h UFC) and late-night cortis...

ea0070aep231 | Bone and Calcium | ECE2020

A follow-up of a patient with osteopetrosis successfully treated with bone marrow transplant at the age of 28

Zhilyaev Viktor , Belaya Zhanna , Arapova Svetlana , Mamedova Elizaveta , Natalia Tarbaeva

Introduction: Osteopetrosis is a rare hereditary disease caused by defective osteoclast differentiation or function. Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for some forms of osteopetrosis. HSCT is usually performed in infancy. Currently there is also experience of HSCT for osteopetrosis in adults1. In this clinical case we describe the follow-up of a patient treated with HSCT1 at the age of 28.<p class="abst...

ea0070aep630 | Pituitary and Neuroendocrinology | ECE2020

Clinical presentations of patients with MEN 1 syndrome and its phenocopies

Dimitrova Diana , Mamedova Elizaveta , Belaya Zhanna , Melnichenko Galina

Introduction: Multiple endocrine neoplasia type 1 (MEN 1) is a rare, autosomal dominant disease caused by mutations in the MEN1 gene. The syndrome predisposes an individual to the development of primary hyperparathyroidism (PHPT), gastroenteropancreatic neuroendocrine tumors (GEP-NETs), pituitary adenomas (PA), as well as other endocrine and non-endocrine tumors that usually manifest at a young age. If a patient with the MEN 1 phenotype does not carry m...

ea0056p172 | Bone ' Osteoporosis | ECE2018

Effects of acromegaly on plasma microRNA levels relevant to bone metabolism.

Grebennikova Tatiana , Belaya Zhanna , Nikitin Alexey , Solodovnikov Alexander , Melnichenko Galina

Molecular basis of the bone disorders in patients with acromegaly are largely unknown.Objective: To investigate microRNAs (miRNA) expression profiles that regulate bone metabolism in plasma samples from patients with acromegaly.Materials and methods: Fasting plasma samples were taken from consecutive subjects with biochemically confirmed active acromegaly and healthy volunteers matched by age, sex and BMI. IGF1 was measured by an e...